Table 2.

Clinical trials of PARP inhibitors as maintenance in the recurrent setting.

Study	Phase	Population	Study Arm	Control Arm	Results
Study-19 NCT00753545	II	Recurrent HG (G2 or 3) OC/FP/PPC ≥2 platinum-based chemotherapy With an objective response to the platinum regimen	Olaparib 400 mg BID	Placebo	gBRCAm PFS 11.2 vs. 4.3 m HR 0.18 (95% CI, 0.10–0.31)
SOLO-2 NCT01874353	III	Recurrent OC/FP/PPC ≥2 platinum-based chemotherapy With an objective response to the platinum regimen BRCAm	Olaparib 300 mg BID	Placebo	PFS 19.1 vs. 5.5 m HR 0.30 (95% CI, 0.22–0.41)
NOVA NCT01847274	III	Recurrent HGSOC/FP/PPC ≥2 platinum-based chemotherapy Platinum sensitive (>6 months)	Niraparib 300 mg daily	Placebo	gBRCAm PFS: 21.0 vs. 5.5 m HR 0.27 (95% CI, 0.17–0.41) Non-gBRCA PFS 9.3 vs. 3.9 m HR 0.45 (95% CI, 0.34–0.61)
ARIEL-3 NCT01968213	III	Recurrent HGSOC/endometrioid (or FP/PPC) ≥2 platinum-based chemotherapy Platinum sensitive (>6 months) ≤1 non-platinum chemotherapy CR/PR platinum-based chemotherapy	Rucaparib 600 mg BID	Placebo	ITT PFS 10.8 m vs. 5.4 m HR 0.37 (95% CI, 0.30–0.45) BRCAm PFS 16.6 m vs. 5.4 m HR 0.23 (95% CI, 0.16–0.34)